Journal of Clinical LipidologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• Contents
• Discussions

Pages: 1  2  

Discussion on dietary fatEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dr. Brown: Welcome to this roundtable discussion on dietary fat. As you know, the issues regarding fat in the diet are under constant evaluation, and our understanding of the role that fat plays in the diet continues to change in light of new discoveries. We have recognized that saturated fat is a major contributor to increased cholesterol levels and the coronary event rate in various societies around the globe. Although there has long been an emphasis on reducing total fat in the diet, from a practical perspective the attempt was to reduce saturated fats and cholesterol since most fat was coming from animal sources. It wa...
Source: Journal of Clinical Lipidology - September 21, 2009 Category: Lipidology Authors: W. Virgil Brown, Wahida Karmally, Penny Kris-Etherton, Lawrence R. Rudel Tags: Clinical Lipidology Roundtable Discussion Source Type: journals

From the Editor-in-ChiefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This month, our Roundtable discussion focused on the confusing issue of dietary fats. It has been argued for several decades that lowering the fat in the diet would reduce vascular disease, with emphasis on saturated fats and cholesterol. However, this group of experts brought several more complex issues to the table. The absolute amount of fat may be less important than previously perceived, and the value of adjusting the nature of the fat with regard to monounsaturated and polyunsaturated fats seems to have taken on more importance. In attempting to design the most healthful diet, there was consensus on attempting to red...
Source: Journal of Clinical Lipidology - September 21, 2009 Category: Lipidology Authors: W. Virgil Brown Tags: Foreword Source Type: journals

Efficacy and tolerability of multidrug therapy for hypertriglyceridemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: In a 2-year follow-up of 40 individuals on multidrug therapy (average of 3.5 drugs) for severe hypertriglyceridemia, combination therapy was efficacious and well tolerated. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 15, 2009 Category: Lipidology Authors: Venkateshwar R. Polsani, Vijay Nambi, Salim S. Virani, Danièle Zoch, Eric Y. Yang, Peter H. Jones, Christie M. Ballantyne Tags: Original Articles Source Type: journals

Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering—lipoprotein changes and interactions: the SANDS studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: In diabetic adults with no previous cardiovascular events, treatment to current targets for lipids and systolic blood pressure reduces atherosclerosis progression and when more aggressive targets are met, atherosclerosis regresses. The aggressive targets for LDL-C and non-HDL-C appeared to be the main determinants of CIMT regression and were more predictive of this outcome than changes in LDL-P or apoB. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 13, 2009 Category: Lipidology Authors: Wm. James Howard, Marie Russell, Jerome L. Fleg, Mihriye Mete, Tauqeer Ali, Richard B. Devereux, James M. Galloway, James D. Otvos, Robert E. Ratner, Mary J. Roman, Angela Silverman, Jason G. Umans, Neil J. Weissman, Charlton Wilson, Barbara V. Howard Tags: Original Articles Source Type: journals

News from the NLAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
If you haven't visited our new website at www.lipid.org lately, you'll be surprised at the changes we've enacted. Our previous site was a directory of resources and news about your association, but today it's a full-fledged social networking and collaborative workspace. These changes bring a wealth of new information to your fingertips, and more importantly they make it easier for you to contribute to the NLA and interact with your colleagues. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 13, 2009 Category: Lipidology Tags: Foreword Source Type: journals

The identification of occult cardiovascular disease through the use of a novel biomarker: a case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Coronary artery disease (CAD) is the leading cause of death and disability in the United States. Although traditional risk factors are helpful in global risk assessment, often these population risk estimations lack the necessary precision when applied to an individual. Acknowledging the limitations of traditional risk factors to precisely assess cardiovascular risk among many persons, the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) recognizes the potential of bioinflammatory markers to more properly assess hidden cardiovascular risk as an adjunct to traditional risk factor assessment. A newl...
Source: Journal of Clinical Lipidology - September 9, 2009 Category: Lipidology Authors: Bradley Bale, Amy Doneen, Michael Wegner Tags: Case Studies Source Type: journals

High plasma high-density lipoprotein levels, very low cardiovascular risk profile, and subclinical carotid atherosclerosis in postmenopausal womenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Subclinical carotid ATS is present in one-third of middle-aged women independently of conventional risk factors. A greater ATS prevalence was associated with very high HDL values. We could not find association between ATS and HDL dysfunction. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 31, 2009 Category: Lipidology Authors: Shlomo Keidar, Ido Bogner, Aviva Gamliel-Lazarovich, Ronit Leiba, Bianca Fuhrman, Efim Kouperberg Tags: Original Articles Source Type: journals

Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: P-OM3 induces changes in sizes, concentrations, and compositions of lipoproteins that may have relevance for the atherothrombotic process. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 31, 2009 Category: Lipidology Authors: Michael H. Davidson, Kevin C. Maki, Harold Bays, Roderick Carter, Christie M. Ballantyne Tags: Original Articles Source Type: journals

Medical management of patients before the incidence of a cardiovascular eventEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Objective: We sought to examine the diagnoses and medical management patterns of patients before the incidence of a cardiovascular (CV) event.Methods: A retrospective study of claims data from a national managed care plan was conducted. Eligible patients had a myocardial infarction, stroke, or revascularization between January 1, 2004 and December 31, 2005, and at least 3 years of continuous enrollment before the CV event. Patients were stratified by whether or not they had a diagnosis of atherosclerosis in the 3 years before the CV event. Diagnostic testing, lipid monitoring, and statin treatment patterns were assessed du...
Source: Journal of Clinical Lipidology - August 31, 2009 Category: Lipidology Authors: Michael H. Davidson, Kathleen M. Fox, Sanjay K. Gandhi, Robert L. Ohsfeldt, James M. McKenney Tags: Original Articles Source Type: journals

News from the NLAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We are now underway with activities at the Foundation of the NLA. The aim of the Foundation is to enhance NLA objectives in education and research in clinical lipidology by conducting independent projects and also by making grants to qualified applicants. The Foundation of the NLA will increase our ability to support professional outreach and education, promote public awareness of critical issues in public health, and liaise with related organizations who share Foundation goals. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 26, 2009 Category: Lipidology Source Type: journals

Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and womenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Lower serum 25(OH)D is associated with the metabolic syndrome and adverse values for some metabolic syndrome risk factors, particularly the HDL-C concentration. Research is warranted to assess whether increasing vitamin D intake will improve the metabolic cardiovascular risk factor profile. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 20, 2009 Category: Lipidology Authors: Kevin C. Maki, Martyn R. Rubin, Les G. Wong, Jamie F. McManus, Christopher D. Jensen, John W. Marshall, Andrea Lawless Tags: Original Articles Source Type: journals

Niacin and cholesterol: The history of a discoveryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Research discoveries do not follow a simple path from A to B although this may appear to be the case to those not familiar with the history of a discovery. A simple observation made by one person eventually led to the development of the modern paradigm, the vitamins-as-treatment paradigm but the pathway was tortuous and difficult and depended upon events that were unpredictable. This then is a brief look at how an observation I made on myself opened up the whole field of nutritional medicine and paved the way for the use of vitamins and other nutrients in optimum doses in spite of intense opposition led by followers of the...
Source: Journal of Clinical Lipidology - July 20, 2009 Category: Lipidology Authors: A. Hoffer Tags: Editorial Articles Source Type: journals

From the Editor-in-ChiefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The reduction of blood cholesterol by nicotinic acid and most of its clinical adverse effects have been known for more than 50 years. The initial observation was described in 1955 in a letter to the editor of the Archives of Biochemistry and Biophysics from Rudolf Altschul, Abram Hoffer, and J.D. Stephen (Archives of Biochemistry and Biophysics 1955;54:558−559). They reported that cholesterol was reduced in hypercholesterolemic rabbits 4 hours after injecting niacin. They therefore undertook initial experiments in humans. During a single day of treatment, oral doses of 1 g were given in the morning, at bedtime, and the ...
Source: Journal of Clinical Lipidology - July 20, 2009 Category: Lipidology Authors: W. Virgil Brown Tags: Foreword Source Type: journals

Adiponectin, leptin, and lipid profile in type 1 diabetic children and adolescentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: The results of this study suggest that blood leptin but not adiponectin concentrations have a significant correlation with indices of glycemic control. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 14, 2009 Category: Lipidology Authors: Awatif M. Abd El-Maksoud, Mohammed H. El Hefnawy, Abdel-Rahman B. Abdel-Ghaffar, Emad F. Eskander, Hanaa H. Ahmed, Dina M. Seoudi, Shaymaa M.M. Yahya, Ibrahim H. Kamal Tags: Original Articles Source Type: journals

Acute exercise and impaired glucose tolerance in obese humansEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These findings suggest that acute aerobic exercise can reduce regional arterial stiffness in obese subjects with IGT by possibly improving glucose metabolism, independent of changes in oxidative stress. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 14, 2009 Category: Lipidology Authors: Conor M. McClean, Andrea M. McNeilly, Tom R. Trinick, Marie H. Murphy, Ellie Duly, Jim McLaughlin, Jane McEneny, George Burke, Gareth W. Davison Tags: Original Articles Source Type: journals

Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentrationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammatory biomarker that is associated with increased cardiovascular disease risk independent of and additive to traditional risk factors. Lp-PLA2 activity is correlated with the degree of inflammation in the atherosclerotic plaque. In human blood, approximately 80% of Lp-PLA2 is associated with low-density lipoproteins (LDL). Thus, it is hypothesized that changes in Lp-PLA2 should imitate the changes in the LDL cholesterol.Objective: In this present study, we examined the efficacy of lifestyle intervention and combination lipid-lowering therapy on...
Source: Journal of Clinical Lipidology - July 5, 2009 Category: Lipidology Authors: Kota J. Reddy, Manmeet Singh, Richard R. Batsell, Joey R. Bangit, Rekha A. Miraskar, Misbah S. Zaheer, Carol Cockerham, Michael Wegner Tags: Original Articles Source Type: journals

Regulation of human stearoyl-CoA desaturase by omega-3 and omega-6 fatty acids: Implications for the dietary management of elevated serum triglyceridesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Diets enriched in LA, ALA, and by metabolic inference EPA, can regulate SCD activity at the level of transcription, a nutritional intervention that may be useful in the management of increased levels of serum triglycerides in cardiometabolic disorders. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - June 21, 2009 Category: Lipidology Authors: Rodney A. Velliquette, Peter J. Gillies, Penny M. Kris-Etherton, John W. Green, Guixiang Zhao, John P. Vanden Heuvel Tags: Original Articles Source Type: journals

In defense of the metabolic syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Diagnosis of the metabolic syndrome provides a major risk factor for all forms of cardiovascular disease and guidance in prevention. The confusing issue of its being a “true syndrome,” with features having common causality or just a collection of very prevalent abnormalities, has been debated. However, it has been implied that if the latter is true, this concept is of little value. The significant clinical utility of the inclusive term metabolic syndrome and its strong association with all forms of cardiovascular disease has been documented. Clinical investigations, now available in the literature, confirm its power in...
Source: Journal of Clinical Lipidology - June 21, 2009 Category: Lipidology Authors: Thomas F. Whayne Tags: Editorial Articles Source Type: journals

Appropriate use of noninvasive vascular measures in the prevention of arterial disease†Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dr. W.V. Brown: Thank you for joining me. We have Dr. Alan Brown from the Midwest Heart Specialists and Drs. Paolo Raggi and Laurence Sperling from Emory University School of Medicine. We're here to discuss noninvasive measures in primary prevention of clinical arterial disease. There is a great deal of uncertainty in the meaning of risk factors in the individual patient. The Framingham Risk Functions supplemented with other measures such as family history or C-reactive protein work well in groups of significant size, but clinicians know well that coronary artery disease tends to surprise you in both its appearance in thos...
Source: Journal of Clinical Lipidology - June 16, 2009 Category: Lipidology Authors: W. Virgil Brown, Alan S. Brown, Paolo Raggi, Laurence S. Sperling Tags: Clinical Lipidology Roundtable Discussion Source Type: journals

From the Editor-in-ChiefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In 2009, several trends are developing in the management of lipoproteins as contributors to the risk of arteriosclerotic vascular disease. I have specifically avoided the use of “lipoprotein disorders” as a term to describe the challenge before us. The risk of developing vascular disease in large populations is continuous and positively related to low-density and very–low-density lipoprotein concentrations throughout the range of values observed in surveys. If anything has become clear, the common human plasma concentrations of non-HDL and particularly LDL are contributing to the surreptitious development of this dis...
Source: Journal of Clinical Lipidology - May 11, 2009 Category: Lipidology Authors: W. Virgil Brown Tags: Foreword Source Type: journals

Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: The Adult Treatment Panel III guideline recommends a low-density lipoprotein-cholesterol (LDL-C) goal of (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 5, 2009 Category: Lipidology Authors: Joseph P. Vande Griend, Joseph J. Saseen Tags: Original Articles Source Type: journals

Lipid-altering effects of different formulations of hydroxypropylmethylcelluloseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: This pilot study provides preliminary evidence to support the efficacy of various formulations of HPMC for reducing cholesterol carried by atherogenic particles in men and women with primary hypercholesterolemia. Additional research will be required to more clearly define the roles of viscosity and dosage on the lipid-altering effects of HPMC. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 5, 2009 Category: Lipidology Authors: Kevin C. Maki, Michael L. Carson, W.H. Kerr Anderson, Jeffrey Geohas, Matthew S. Reeves, Mildred V. Farmer, Maciej Turowski, Marvin Miller, Valerie N. Kaden, Mary R. Dicklin, Tia M. Rains Tags: Original Articles Source Type: journals

The effects of diets enriched in beta-glucans on blood lipoprotein concentrationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Dietary beta-glucans lower the blood concentrations of cholesterol in animals and humans. Recent studies have uncovered mechanisms by which dietary beta-glucans may regulate cholesterol homeostasis. There is evidence that beta-glucans sequester bile acids in the intestine, reducing their reabsorption and return to the liver. Reducing hepatic bile acid concentrations activates the enzyme CYP7A1, which converts cholesterol into bile acids. This action leads to a reduction of hepatic cell cholesterol content, which up-regulates low-density lipoprotein (LDL) receptor synthesis and thereby accelerates the transportati...
Source: Journal of Clinical Lipidology - May 5, 2009 Category: Lipidology Authors: Jiezhong Chen, Xu-Feng Huang Tags: Review Article Source Type: journals

The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined HyperlipidemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: The combination of niacin and statin has proven value in the management of hyperlipidemia and prevention of heart disease. However, the efficacy of the nonprescription time-release niacin, Slo-Niacin®, is little studied alone and not at all with atorvastatin. We studied Slo-Niacin® and atorvastatin, singly and together, to determine efficacy on the combined abnormalities of triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C).Methods: A total of 42 men and women with LDL-C >130mg/dL and HDL-C (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - May 4, 2009 Category: Lipidology Authors: Robert H. Knopp, Barbara M. Retzlaff, Brian Fish, Alice Dowdy, Barbara Twaddell, Thuy Nguyen, Pathmaja Paramsothy Tags: Original Articles Source Type: journals

Aspirin Decreases Niacin Extended-Release-Induced Flushing in Dyslipidemic Patients: The ASA-Effects Clinical StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Niacin is the most potent agent for increasing HDL-C and has been shown to regress plaque and improve CV outcomes. A common effect of niacin is flushing, which can be managed with aspirin (ASA). However the impact of aspirin is not well-defined. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Robert J. Padley, Moti L. Kashyap, Andrew J. Lewin, Scott L. Krause, Ping Jiang, Roopal B. Thakkar Tags: Abstracts Source Type: journals

Dalcetrapib is not Associated with Changes in the QT Interval Following Multiple Doses in Healthy SubjectsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study evaluated the potential for dalcetrapib to prolong the QT interval. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Michael Derks, Markus Abt, Anne Mwangi, Georgina Meneses-Lorente Tags: Abstracts Source Type: journals

Lack of Clinically Significant Drug−Drug Interactions for Dalcetrapib Coadministered with SimvastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Dalcetrapib, an agent that targets cholesteryl ester transfer protein (CETP), will likely be prescribed on top of statin therapy. The dose of dalcetrapib evaluated in this study is 900mg, which was the highest dose tested in Phase II. The dose chosen for Phase III studies of dalcetrapib is 600mg. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Michael Derks, Markus Abt, Mary Phelan Tags: Abstracts Source Type: journals

Lack of Clinically Significant Drug−Drug Interactions for Dalcetrapib Coadministered with AtorvastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Dalcetrapib, which targets cholesteryl ester transfer protein (CETP), will likely be prescribed on top of statins. The dose of dalcetrapib evaluated in one of the two studies presented here is 900mg, which was the highest dose tested in Phase II. The dose chosen for Phase III studies of dalcetrapib is 600mg. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Michael Derks, Markus Abt, Mary Phelan Tags: Abstracts Source Type: journals

Lack of Clinically Significant Drug−Drug Interactions for Dalcetrapib Coadministered with EzetimibeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Dalcetrapib, an agent that targets cholesteryl ester transfer protein (CETP), will likely be prescribed in combination with other lipid-modifying drugs such as ezetimibe. The dose of dalcetrapib evaluated in this study is 900mg, which was the highest dose tested in Phase II. The dose chosen for Phase III studies of dalcetrapib is 600mg. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Michael Derks, Markus Abt, Mary Phelan Tags: Abstracts Source Type: journals

Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20mg Compared with Rosuvastatin 10mg in High-Risk Patients with and Without Type 2 Diabetes Mellitus (T2DM)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Many patients fail to achieve recommended LDL-C goals with statin monotherapy and are at increased risk of coronary events. Hypercholesterolemic patients at high cardiovascular risk who failed to achieve adequate LDL-C lowering with prior statin monotherapy were switched to ezetimibe/simvastatin 10/20mg (EZE/SIMVA) or rosuvastatin 10mg (ROSUVA). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Philippe Brudi, Helena Vaverkova, Michel Farnier, Maurizio Averna, Margus Viigimaa, Qian Dong, Arvind Shah, Amy O. Johnson-Levonas, Luc Missault Tags: Abstracts Source Type: journals

Variant of KIF6 Predicts Coronary Events and Event Reduction During Statin Therapy: Results from CARE, WOSCOPS, PROSPER, and PROVE IT-TIMI 22Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Statins are the drugs of choice for primary and secondary prevention of coronary heart disease; however, response to statin therapy varies among patients. Purpose: To investigate the association of the KIF6 Trp719Arg variant (rs20455) with risk of coronary events and differential response to statin therapy. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: James J. Devlin, KIF6 Collaborators Tags: Abstracts Source Type: journals

Treatment Patterns of Patients Receiving Simvastatin Monotherapy with Abnormalities in HDL-C and/or TG LevelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Generic simvastatin has become the most commonly used statin for the treatment of hypercholesterolemia. However, simvastatin may not improve all lipid values to optimal levels and data from a national managed care dataset suggests that patients with abnormal HDL-C and/or TG on simvastatin monotherapy persist on monotherapy. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: QuynhChau Diem Doan, Silky F. Webb, Woodie M. Zachry Tags: Abstracts Source Type: journals

Long-term Safety and Efficacy of Triple Combination Ezetimibe/Simvastatin+Extended-Release Niacin in Hyperlipidemic PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Guidelines recommend consideration of broad lipid-altering therapies for patients with combined dyslipidemia. Purpose: The safety and efficacy of ezetimibe/simvastatin (E/S) + extended-release niacin (N) was assessed in type IIa and IIb hyperlipidemic patients in a 64-week trial. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: John R. Guyton, Sergio Fazio, Adam Polis, Adeniyi Adewale, Joanne E. Tomassini, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Effect of Baseline Demographic, Lipid, and Metabolic Factors on the Efficacy of Ezetimibe/Simvastatin and Atorvastatin Therapies in Type 2 Diabetes PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Type 2 Diabetes (T2DM) patients are at increased risk for cardiovascular disease (CVD), due partly to dyslipidemia (high TG levels, low HDL-C levels, predominance of small dense, LDL particles). In addition to lifestyle modification, statin therapy aimed at lowering of LDL-C is considered a priority for these patients. Demographic and baseline lipid/metabolic factors such as triglyceride (TG) levels can predict treatment response, yet are not always considered in evaluating treatment efficacy. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Ronald B. Goldberg, John R. Guyton, Theodore Mazzone, Ruth S. Weinstock, Adam Polis, Joanne E. Tomassini, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Long-term Effect of Triple Combination Ezetimibe/Simvastatin+Extended-Release Niacin on Cholesterol Content of Lipoprotein Subclasses in Hyperlipidemic PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Patients with hyperlipidemia are at increased risk for CVD, due partly to dyslipidemia characterized by elevated levels of triglycerides (TG), TG-rich proteins (VLDL, IDL), small, dense LDL, and low levels of HDL-C. As differences in the composition of lipoproteins can influence atherogenicity†, assessment of the lipoprotein subclass profile may aid in risk assessment and in guiding therapeutic decisions. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Sergio Fazio, John R. Guyton, Adam Polis, Adeniyi Adewale, Joanne E. Tomassini, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Influence of Age/Gender/Race on the Efficacy of Ezetimibe/Simvastatin vs. Atorvastatin in Metabolic Syndrome Patients with Moderately High/High CHD RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Metabolic syndrome is associated with an increased risk for development of coronary heart disease (CHD). Factors which may influence CHD risk include age, gender, and race. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Jennifer Robinson, Christie M. Ballantyne, Scott M. Grundy, Willa A. Hsueh, Hans-Henrik Parving, Jeffrey B. Rosen, Jianxin Lin, Robert S. Lowe, Arvind K. Shah, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Efficacy of Ezetimibe Added to Atorvastatin vs Uptitration of Atorvastatin in the ElderlyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study assessed the percent (%) change from baseline in low-density lipoprotein cholesterol (LDL-C) and % patients achieving prespecified LDL-C level after 12 wks of ezetimibe 10mg (ezetimibe) added to atorvastatin versus uptitration of atorvastatin in elderly subjects with hyperlipidemia at high risk for coronary heart disease. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Franklin J. Zieve, Nanette K. Wenger, Ori Ben-Yehuda, Christian Constance, Steve Bird, Raymond Lee, Mary E. Hanson, Charlotte Jones-Burton, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20mg Compared with Rosuvastatin 10mg in High-Risk Patients with and Without Type 2 Diabetes MellitusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study evaluated efficacy of switching hypercholesterolemic patients at high cardiovascular risk who failed to achieve adequate lowering of LDL-C with prior statin monotherapy to ezetimibe/simvastatin (EZE/SIMVA) versus rosuvastatin (ROSUVA). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Jennifer Rotonda Tags: Abstracts Source Type: journals

Efficacy and Safety of Ezetimibe/Simvastatin vs. Atorvastatin in Patients with Hypercholesterolemia, Metabolic Syndrome, and Atherosclerotic Vascular DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Atherosclerotic vascular disease (AVD) and metabolic syndrome (MetSyn) are each associated with a higher risk of coronary heart disease. Purpose: The aim of this post hoc analysis was to assess % change from baseline in lipids and % patients reaching LDL-C (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Jennifer Robinson, Christie Ballantyne, Scott Grundy, Willa Hsueh, Hans-Henrik Parving, Jeffrey Rosen, Jianxin Lin, Arvind Shah, Mary E. Hanson, Andrew Tershakovec Tags: Abstracts Source Type: journals

Comparative Efficacy of Ezetimibe Added to Atorvastatin vs. Uptitration of Atorvastatin in Attainment of Recommended Lipid Targets in Patients at High Risk for Coronary Heart DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Low-density lipoprotein cholesterol (LDL-C) has been identified by treatment guidelines as a major target for treatment of patients at high risk for coronary heart disease (CHD). Total cholesterol, total cholesterol/HDL-C ratio and Apo B have been identified by some guidelines as additional targets, and hs-CRP as a potentially useful risk indicator. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Scott E. Conard, Lawrence Leiter, Harold Bays, Arvind Shah, Jianxin Lin, Mary E. Hanson, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Long-term Effect of Combination Ezetimibe/Simvastatin+Extended-Release Niacin on Cholesterol Content of Lipoprotein Subclasses in Patients with HyperlipidemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: The increased CVD risk of hyperlipidemic (HL) patients is only partly quantified by the standard lipid panel (TG, cholesterol, LDL and HDL). As differences in lipoprotein composition can influence atherogenicity, assessment of the lipoprotein subclass profile may aid in risk assessment and in guiding therapy. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Joanne E. Tomassini, Sergio Fazio, John Guyton, Andrew Tershakovec Tags: Abstracts Source Type: journals

Effect of Ezetimibe Added to Atorvastatin on Lipoprotein Subclass Cholesterol Content in Patients with Higher Versus Lower Triglyceride LevelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Cholesterol carried by different lipoprotein subclasses may differ in the potential to promote atherosclerotic coronary heart disease (CHD). However, data related to changes in these lipid parameters to ezetimibe therapy are limited. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Harold Edward Bays, Mary E. Hanson, Erin Jensen, Arvind Shah, Lawrence Leiter, Scott Conard, Andrew M. Tershakovec, Steve Bird Tags: Abstracts Source Type: journals

Does Baseline Body Mass Index, Fasting Blood Sugar, and High-Sensitivity C-Reactive Protein Influence the Efficacy of Adding Ezetimibe to Atorvastatin Versus Doubling the Atorvastatin Dose in Moderately High and High Coronary Heart Disease Risk Patients?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Obesity, metabolic and inflammatory factors increase coronary heart disease (CHD) risk, and conceivably affect lipid altering drug efficacy. Purpose: Assess the influence of obesity, impaired fasting glucose, and inflammatory status on the efficacy of ezetimibe 10mg (E) added to atorvastatin (A) vs. doubling of A in hypercholesterolemic patients at moderately high risk (MHR- none with diabetes) or high risk (HR-53% with diabetes) for CHD. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Harold Edward Bays, Scott Conard, Lawrence A. Leiter, Steven Bird, Arvind K. Shah, Jianxin Lin, Robert S. Lowe, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Dalcetrapib in High-Risk Patients with Type 2 Diabetes Mellitus and/or Metabolic SyndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Even with statin therapy, cardiovascular (CV) events account for 70–80% of deaths in patients with type 2 diabetes mellitus (T2DM). Reduced high-density lipoprotein cholesterol (HDL-C) levels often accompany T2DM and metabolic syndrome (MetSyn), and constitute an independent CV risk factor. Dalcetrapib is a selective inhibitor of cholesteryl ester transfer protein (CETP) activity that raises HDL-C in both healthy subjects and those with hypercholesterolemia. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Michael H. Davidson, Anton F.H. Stalenhoef, Jennifer G. Robinson, Regina Duttlinger-Maddux, David Kallend, Harold Bays Tags: Abstracts Source Type: journals

Safety and Tolerability of Dalcetrapib in High-Risk Patients with Type 2 Diabetes and/or Metabolic SyndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Cardiovascular-related events account for 70–80% of deaths in individuals with type 2 diabetes (T2DM), even following intensive statin therapy. Low levels of high-density lipoprotein cholesterol (HDL-C), characteristic in T2DM and metabolic syndrome (MetSyn), constitute an independent cardiovascular risk factor. Dalcetrapib, a selective inhibitor of cholesteryl ester transfer protein (CETP) activity, has been shown to effectively raise HDL-C levels. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Anne Carol Goldberg, Anton F.H. Stalenhoef, Regina Duttlinger-Maddux, David Kallend Tags: Abstracts Source Type: journals

Effect of Metabolic Syndrome Factors and Insulin Resistance on Ezetimibe/Simvastatin and Atorvastatin Treatment Efficacy in Patients with Metabolic Syndrome and Moderately High/High CHD RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Metabolic syndrome (MetSyn) affects about 25% of the US population. MetSyn associated factors (abdominal obesity, low HDL-C; and elevated triglycerides (TG), blood pressure and fasting glucose) as well as insulin resistance (IR) may be associated with increased coronary heart disease (CHD) risk. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Jeffrey B. Rosen, Christie M. Ballantyne, Scott M. Grundy, Willa A. Hsueh, Hans-Henrik Parving, Jennifer G. Robinson, Jianxin Lin, Robert S. Lowe, Arvind K. Shah, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Efficacy and Safety of Fenofibric Acid and Rosuvastatin Combination Therapy in Women 55 Years or Older (Post-Menopausal) with Mixed DyslipidemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Coronary heart disease (CHD) risk sharply increases in women after 50 years of age, which may be due in part to increased LDL-C levels and changes in LDL-C phenotype (more small, dense particles) associated with menopause. While the NCEP ATP III guidelines recommend treating LDL-C to goal before treating other lipids, increasing evidence suggests that further cardiovascular benefit may be achieved by also targeting other components of the lipid profile, such as HDL-C and TG. The presence of mixed dyslipidemia, the abnormal lipid triad characterized by high TG, low HDL-C and elevated LDL-C, further increases CHD r...
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Anne Carol Goldberg, Nanette K. Wenger, Dawn M. Carlson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, Michael Cressman, James C. Stolzenbach Tags: Abstracts Source Type: journals

Do Age, Gender, and Race Affect the Efficacy of Ezetimibe Plus Atorvastatin vs. Doubling the Atorvastatin Dose in Moderately High and High CHD Risk Patients?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Age, gender, and race are factors that influence atherosclerotic coronary heart disease (CHD) risk, and may conceivably affect the efficacy of lipid-altering drugs. Purpose: Assess the effects of age, gender, and race on atorvastatin (A) and ezetimibe (E) plus A efficacy in hypercholesterolemic patients with (1) moderately high (MHR) or (2) high (HR) CHD risk. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Harold Edward Bays, Scott Conard, Lawrence A. Leiter, Steve Bird, Robert S. Lowe, Andrew M. Tershakovec Tags: Abstracts Source Type: journals

Efficacy and Safety of Colesevelam HCl in Pediatric Patients with Heterozygous Familial HypercholesterolemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Heterozygous familial hypercholesterolemia (heFH) is a genetic disorder resulting in elevated LDL-C, which confers a high risk for a coronary event. The bile acid sequestrant colesevelam HCl is approved for LDL-C lowering in adults. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Sam Misir, Evan A. Stein, David Marais, Tamas Szamosi, Frederick Raal, Daniel Schurr, Elaine M. Urbina, Paul N. Hopkins, Sulekha Karki, Michael Melino Tags: Abstracts Source Type: journals

Treatment with the Combination of Niacin Extended-Release and Simvastatin Reduces Atherogenic Particles in Patients with Mixed DyslipidemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Synopsis: Treatment with the combination of niacin extended-release and simvastatin (NER/S) reduces the number of circulating atherogenic particles in patients with mixed dyslipidemia. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 30, 2009 Category: Lipidology Authors: Richard H. Karas, Moti L. Kashyap, Michael H. Davidson, Roopal B. Thakkar, Ping Jiang, Rhea A. Parreno, Robert J. Padley Tags: Abstracts Source Type: journals